U.S. Markets closed
  • S&P 500

    3,638.35
    +8.70 (+0.24%)
     
  • Dow 30

    29,910.37
    +37.90 (+0.13%)
     
  • Nasdaq

    12,205.85
    +111.44 (+0.92%)
     
  • Russell 2000

    1,855.27
    +10.25 (+0.56%)
     
  • Crude Oil

    45.53
    -0.18 (-0.39%)
     
  • Gold

    1,781.90
    -23.60 (-1.31%)
     
  • Silver

    22.55
    -0.81 (-3.46%)
     
  • EUR/USD

    1.1960
    +0.0047 (+0.3947%)
     
  • 10-Yr Bond

    0.8440
    -0.0340 (-3.87%)
     
  • Vix

    20.84
    -0.41 (-1.93%)
     
  • GBP/USD

    1.3300
    -0.0056 (-0.4216%)
     
  • USD/JPY

    104.0350
    -0.2150 (-0.2062%)
     
  • BTC-USD

    16,793.97
    +69.18 (+0.41%)
     
  • CMC Crypto 200

    329.19
    -8.30 (-2.46%)
     
  • FTSE 100

    6,367.58
    +4.65 (+0.07%)
     
  • Nikkei 225

    26,644.71
    +107.40 (+0.40%)
     

G1 Therapeutics, Inc. (NASDAQ:GTHX) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year

Simply Wall St
·4 min read

Investors in G1 Therapeutics, Inc. (NASDAQ:GTHX) had a good week, as its shares rose 9.7% to close at US$12.06 following the release of its third-quarter results. It looks like a positive result overall, with revenues of US$27m beating forecasts by 6.4%. Statutory losses of US$0.31 per share were roughly in line with what the analysts had forecast. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year.

Check out our latest analysis for G1 Therapeutics

earnings-and-revenue-growth
earnings-and-revenue-growth

Taking into account the latest results, the eight analysts covering G1 Therapeutics provided consensus estimates of US$18.5m revenue in 2021, which would reflect a sizeable 36% decline on its sales over the past 12 months. Per-share losses are expected to explode, reaching US$4.06 per share. Yet prior to the latest earnings, the analysts had been forecasting revenues of US$16.9m and losses of US$3.84 per share in 2021. Overall it looks as though the analysts were a bit mixed on the latest consensus updates. Although there was a nice uplift to revenue, the consensus also made a to its losses per share forecasts.

There was no major change to the consensus price target of US$56.43, with growing revenues seemingly enough to offset the concern of growing losses. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. Currently, the most bullish analyst values G1 Therapeutics at US$82.00 per share, while the most bearish prices it at US$21.00. As you can see the range of estimates is wide, with the lowest valuation coming in at less than half the most bullish estimate, suggesting there are some strongly diverging views on how analysts think this business will perform. With this in mind, we wouldn't rely too heavily the consensus price target, as it is just an average and analysts clearly have some deeply divergent views on the business.

Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. We would highlight that sales are expected to reverse, with the forecast 36% revenue decline a notable change from historical growth of 33% over the last five years. By contrast, our data suggests that other companies (with analyst coverage) in the same industry are forecast to see their revenue grow 20% annually for the foreseeable future. It's pretty clear that G1 Therapeutics' revenues are expected to perform substantially worse than the wider industry.

The Bottom Line

The most important thing to note is the forecast of increased losses next year, suggesting all may not be well at G1 Therapeutics. Fortunately, they also upgraded their revenue estimates, although our data indicates sales are expected to perform worse than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. We have estimates - from multiple G1 Therapeutics analysts - going out to 2024, and you can see them free on our platform here.

Don't forget that there may still be risks. For instance, we've identified 3 warning signs for G1 Therapeutics (1 shouldn't be ignored) you should be aware of.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.